The B Cell Biology Scientific Research Support Component (SRSC) will assist in the generation of novel vaccines that target broad neutralizing antibodies (BnAbs) or other protective B-cell precursors by B lineage immunogen design. The novel vaccines generated by the CHAVI-ID B Cell Focus will be designed to activate the unmutated ancestors (UA) of highly mutated BnAb B cells isolated by flow cytometry. As a parallel strategy, this B Cell Biology SRSC will first isolate human B-cell precursors, and drives their maturation in vitro. BnAb precursors will then be identified and allowed to proliferate, mature and undergo Ig class-switching (CSR) in vitro. In this manner, the B Cell Biology SRSC will complement the work of the B Lineage Immunogen Design teams by identifying and selecting BnAb precursors -unmutated ancestors B cells - that are comparable to, and possibly better than, those inferred from BnAb clonal lineages. This support component will identify, isolate, characterize, and activate de novo B cells capable of generating BnAb responses, allowing the direct study of BnAb UA and intermediate antibody (IA) B cells.
Specific Aims Aim 1. Culture Env-specific immature B cells from human bone marrow in vitro and drive them to express AID and undergo Ig class-switch recombination in vitro to characterize BnAb maturation pathways.
Aim 2. Culture Env-specific immature B cells from humanized Velocimmune? mice in vitro and drive antigen-specific B cells to compete and mature by AID expression and Ig CSR to characterize BnAb maturation pathways.
Aim 3. Immunize immunoglobulin humanized mice with candidate Env vaccines to determine their immunogenicity by characterizing serum antibody responses and hybridoma lines.
This support component will grow human and immunoglobulin humanized mouse B cells in test tubes and these will be used to identify candidate HlV-1 vaccine antigens. This approach will allow novel molecular vaccine designs to be tested inexpensively, rapidly, and ethically.
|Chen, Shuobing; Wu, Jiayi; Lu, Ying et al. (2016) Structural basis for dynamic regulation of the human 26S proteasome. Proc Natl Acad Sci U S A 113:12991-12996|
|Tian, Ming; Cheng, Cheng; Chen, Xuejun et al. (2016) Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell 166:1471-1484.e18|
|Barton, John P; Goonetilleke, Nilu; Butler, Thomas C et al. (2016) Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable. Nat Commun 7:11660|
|Love, Tanzy M T; Park, Sung Yong; Giorgi, Elena E et al. (2016) SPMM: estimating infection duration of multivariant HIV-1 infections. Bioinformatics 32:1308-15|
|Herschhorn, Alon; Ma, Xiaochu; Gu, Christopher et al. (2016) Release of gp120 Restraints Leads to an Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins. MBio 7:|
|Astronomo, Rena D; Santra, Sampa; Ballweber-Fleming, Lamar et al. (2016) Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine 14:97-111|
|Ding, Shilei; Tolbert, William D; PrÃ©vost, JÃ©rÃ©mie et al. (2016) A Highly Conserved gp120 Inner Domain Residue Modulates Env Conformation and Trimer Stability. J Virol 90:8395-409|
|Theiler, James; Yoon, Hyejin; Yusim, Karina et al. (2016) Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine. Sci Rep 6:33987|
|Abdul-Jawad, Sultan; Ondondo, Beatrice; van Hateren, Andy et al. (2016) Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition. Mol Ther 24:375-84|
|Jeffries Jr, T L; Sacha, C R; Pollara, J et al. (2016) The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells. Mucosal Immunol 9:414-27|
Showing the most recent 10 out of 160 publications